Cancer Genetics, Inc. (CGIX) insider have most recently took part in a trading activity. On Dec 15, 2017 Roberts John A, COO bought 12,200 shares having total worth of $24,400 at the price of $2 per share, following the transaction a total of 12,200 shares owned by Roberts John A.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 7 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 6 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Cancer Genetics, Inc. (CGIX) last announced its earnings results on Nov 9, 2017. The company reported -0.16 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.12 by $0.04. The company had revenue of $8 million for the quarter, compared to the consensus estimate of $8 million. During the same quarter in the previous year, the company posted -0.23 earnings per share. The company’s revenue for the quarter was up 19% on a year-over-year basis.
|earnings per share||-0.16||-0.16||0.00||-0.15||-0.23||-0.28||-0.39||-0.47||-0.56||-0.51|
Cancer Genetics, Inc. was incorporated in the State of Delaware on April 8, 1999. The Company develops and commercializes proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. Its proprietary tests target cancers that are difficult to prognose and for which it is difficult to predict treatment outcomes using currently available techniques. These cancers include hematological, urogenital and HPV-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In addition, It also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services, to oncologists and pathologists at hospitals, cancer centers, reference laboratories and physician offices. The non-proprietary laboratory testing services include molecular testing, sequencing, mutational analysis, flow cytometry testing, histology testing and cytology testing. Till date, it has generated most of the revenues through the sale of non-proprietary testing services to a limited number of oncologists, pathologists, and community hospitals located mostly in the eastern and Midwestern United States.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018